Keyron develops the ForePass® device, a fully endoscopic procedure that replicates the effects of metabolic surgery to reverse obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) without surgical intervention. This technology offers a safer and less invasive alternative to traditional gastric bypass procedures, addressing the high risks and costs associated with metabolic surgery.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HWFounders
Product
Problem
Metabolic surgery, while effective for reversing obesity, type 2 diabetes, and NASH, carries significant risks and high costs, making it inaccessible for many patients. Current non-surgical options may lack the efficacy of surgical interventions.
Solution
Keyron is developing ForePass, a fully endoscopic, non-surgical procedure designed to replicate the benefits of metabolic surgery. The ForePass procedure aims to reverse obesity, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and liver fibrosis without incisions. By mimicking the mechanisms of action of gastric bypass, ForePass intends to offer a safer and less invasive alternative, bridging the gap between the safety of gastric balloons and the effectiveness of gastric bypass surgery. Preclinical data has demonstrated a reversal of diabetes and NASH in rodents and safety in swine.
Target Audience
The primary target audience includes individuals with diabesity (diabetes and obesity), NASH, and liver fibrosis, as well as physicians specializing in gastroenterology, endocrinology, and metabolic disorders.
Features
- Fully endoscopic procedure, eliminating the need for surgical incisions
- Designed to replicate the mechanism of action of metabolic surgery
- Aims to reverse obesity, diabetes, NASH, and liver fibrosis
- Intended to provide similar efficacy to gastric bypass with the safety profile of gastric balloons